

DRUG RECEPTORS AND THEIR EFFECTORS

Previously published volumes

- 1970 Aldridge: *Mechanisms of Toxicity*
- 1971 Rabin and Freedman: *Effects of Drugs on Cellular Control Mechanisms*
- 1972 Rang: *Drug Receptors*
- 1973 Callingham: *Drugs and Transport Processes*
- 1974 Parsons: *Peptide Hormones*
- 1975 Grahame-Smith: *Drug Interactions*
- 1976 Roberts: *Drug Action at the Molecular Level*
- 1977 Hughes: *Centrally Acting Peptides*
- 1978 Turk and Parker: *Drugs and Immune Responsiveness*
- 1980 Sandler: *Enzyme Inhibitors as Drugs*

BIOLOGICAL COUNCIL
The Co-ordinating Committee for Symposia
on Drug Action

DRUG RECEPTORS AND THEIR EFFECTORS

Edited by

NIGEL J. M. BIRDSALL

*National Institute for Medical Research,
Mill Hill, London*

M

© Institute of Biology Endowment Trust Fund 1981

Softcover reprint of the hardcover 1st edition 1981

All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission

First published 1981 by

The Scientific and Medical Division

MACMILLAN PUBLISHERS LTD

London and Basingstoke

Companies and representatives throughout the world

ISBN 978-1-349-05557-9

ISBN 978-1-349-05555-5 (eBook)

DOI 10.1007/978-1-349-05555-5

Biological Council Co-ordinating Committee for Symposia on Drug Action

Report of a symposium held on 31 March and 1 April 1980 in London at The Middlesex Hospital Medical School

Sponsored by:

The Biochemical Society
British Association for Psychopharmacology
British Biophysical Society
British Pharmacological Society
Society for Experimental Biology
The Nutrition Society
The Pharmaceutical Society of Great Britain
The Physiological Society

The Organising Committee is grateful for generous financial help from:

Abbott Laboratories Limited	Miles Laboratories Limited
Astra Pharmaceuticals Limited	Pfizer Limited
Astra Läkemedel AB	Reckitt and Coleman Limited
Beecham Pharmaceuticals Research Division	Roche Products Limited
The Boots Company Limited	Smith Kline and French Laboratories Limited
Fisons Limited	E. R. Squibb and Sons Limited
Glaxo (1972) Charity Trust	The Upjohn Company
Imperial Chemical Industries Limited	Warner-Lambert/Parke-Davis
Kabi AB	The Wellcome Foundation
Dr Karl Thomae GmbH	Winthrop Laboratories

Organised by a Committee consisting of:

N. J. M. Birdsall (Chairman and Hon. Secretary)
J. W. Black
S. R. Nahorski
J. A. Parsons
H. P. Rang

Symposium contributors

J. Axelrod, Section on Pharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20205, USA

M. J. Berridge, ARC Unit of Invertebrate Chemistry and Physiology, Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3EJ, UK

C. P. Berrie, Division of Molecular Pharmacology, National Institute for Medical Research, Mill Hill, London NW7 1AA, UK

N. J. M. Birdsall, Division of Molecular Pharmacology, National Institute for Medical Research, Mill Hill, London NW7 1AA, UK

A. J. Blume, Department of Physiological Chemistry and Pharmacology, Roche Institute of Molecular Biology, Nutley, New Jersey 07110, USA

P. Boyd-Leinen, Department of Cell Biology, Section of Biochemistry, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55901, USA

A.S.V. Burgen, Division of Molecular Pharmacology, National Institute for Medical Research, Mill Hill, London NW7 1AA, UK

D. Colquhoun, Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, UK

S. Eimerl, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel

B. F. Erlanger, Department of Microbiology, Columbia University Cancer Center/Institute of Cancer Research, New York, New York 10032, USA

D. M. Fambrough, Department of Embryology, Carnegie Institution of Washington, 115 West University Parkway, Baltimore, Maryland 21210, USA

W. Fischli, Department of Molecular Biology and Biophysics, Swiss Federal Institute of Technology (ETH), CH-8093 Zürich, Switzerland

B. Gysin, Department of Molecular Biology and Biophysics, Swiss Federal Institute of Technology (ETH), CH-8093 Zürich, Switzerland

F. Hirata, Section on Pharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20205, USA

E. C. Hulme, Division of Molecular Pharmacology, National Institute for Medical Research, Mill Hill, London NW7 1AA, UK

R. Jürss, Department of Biochemistry, Imperial College of Science and Technology, London SW7, UK

O. L. Kon, Department of Cell Biology, Section of Biochemistry, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55901, USA

M. Korner, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel

M. E. Krouse, Division of Biology, California Institute of Technology, Pasadena, California 91125, USA

R. Laugier, Unite 31, Institut National de la Santé et de la Recherche Médicale, 46 Chemin de la Gaye, 13009 Marseille, France

H. A. Lester, Division of Biology,
California Institute of Technology,
Pasadena, California 91125, USA

A. Maerlicke, Max-Planck-Institut,
Rheinlanddamm 201, D-4600 Dortmund,
German Federal Republic

G. Martin-Dani, Graduate School of
Medicine, Mayo Clinic, Rochester,
Minnesota 55901, USA

J. M. Nerbonne, Division of Biology,
California Institute of Technology,
Pasadena, California 91125, USA

G. Neufeld, Department of Biological
Chemistry, The Hebrew University of
Jerusalem, Jerusalem, Israel

A. Nishiyama, The Second Department
of Physiology, Yamagata University
School of Medicine, Zao, Yamagata
990-23, Japan

A. Noma, National Institute of Physio-
logical Sciences, 444 Okazaki, Japan

W. Osterrieder, II. Physiologisches Institut
der Universität des Saarlandes, 6650
Homburg/Saar, German Federal Republic

O. H. Petersen, Department of
Physiology, The University, Dundee
DD1 4HN, Scotland

H. G. Philpott, Department of Physiology,
The University, Dundee DD1 4HN,
Scotland

H. Prinz, Max-Planck-Institut,
Rheinlanddamm 201, D-4600 Dortmund,
German Federal Republic

D. F. Sargent, Department of Molecular
Biology and Biophysics, Swiss Federal
Institute of Technology (ETH), CH-8093
Zürich, Switzerland

P. Schoch, Department of Molecular
Biology and Biophysics, Swiss Federal
Institute of Technology (ETH), CH-8093
Zürich, Switzerland

M. Schramm, Department of Biological
Chemistry, The Hebrew University of
Jerusalem, Jerusalem, Israel

R. Schwyzer, Department of Molecular
Biology and Biophysics, Swiss Federal
Institute of Technology (ETH), Zürich,
Switzerland

T. C. Spelsberg, Department of Cell
Biology, Section of Biochemistry, Mayo
Medical School, Mayo Clinic, Rochester,
Minnesota 55901, USA

W. Trautwein, II. Physiologisches Institut
der Universität des Saarlandes, 6650
Homburg/Saar, German Federal Republic

N. H. Wassermann, Department of Micro-
biology, Columbia University Cancer
Center/Institute of Cancer Research, New
York, New York 10032, USA

Contents

<i>Sponsoring societies</i>	v
<i>Bodies from whom financial support was received</i>	v
<i>Symposium contributors</i>	vii
1. Introduction. N. J. M. Birdsall	1
2. Potassium Channels and the Muscarinic Receptor in the Sino-atrial Node of the Heart. W. Trautwein, W. Osterrieder and A. Noma	5
3. Interactions of Muscarinic Receptors with Guanine Nucleotides and Adenylate Cyclase. E. C. Hulme, C. P. Berrie, N. J. M. Birdsall and A. S. V. Burgen	23
4. NG108-15 Opiate Receptors: Characterisation as Binding Sites and Regulators of Adenylate Cyclase. A. J. Blume	35
5. Phospholipid Methylation and Receptor-mediated Transmission of Biological Signals through Membranes. J. Axelrod and F. Hirata	51
6. Implantation of Hormone Receptors: Fusion of Membrane Components with Cell Membranes. G. Neufeld, M. Korner, S. Eimerl and M. Schramm	59
7. Hormonal Control of Ion Permeability of the Pancreatic Acinar Cell Membrane Mediated by Intracellular Calcium. O. H. Petersen, A. Nishiyama, R. Laugier and H. G. Philpott	63
8. Phosphatidylinositol Metabolism and Calcium Gating in a 5-HT Receptor System. M. J. Berridge	75
9. Interaction of Fluorescent Analogues of Acetylcholine with Nicotinic Acetylcholine Receptors and Acetylcholine Esterase. H. Prinz, R. Jürss and A. Maelicke	87
10. Light-activated Compounds as Probes for Nicotinic Acetylcholine Receptors. H. A. Lester, M. E. Krouse, J. M. Nerbonne, N. H. Wassermann and B. F. Erlanger	97
11. The Kinetics of Conductance Changes at Nicotinic Receptors of the Muscle End-plate and of Ganglia. D. Colquhoun	107
12. Adrenocorticotrophin-(1-24)-tetrakosipeptide Spans Lipid Membranes: Experiments with Liposomes. R. Schwyzer, W. Fischli, B. Gysin, D. F. Sargent and P. Schoch	129
13. Novel Regulations in Steroid Action: Role of Receptor Subunits and Chromosomal Proteins in Nuclear Binding. T. C. Spelsberg, P. Boyd-Leinen, G. Martin-Dani and O. L. Kon	133
14. Biosynthesis and Turnover of Nicotinic Acetylcholine Receptors. D. M. Fambrough	155
<i>The summing up.</i> Sir Arnold Burgen	165
<i>Author index</i>	166
<i>Subject index</i>	177